Werewolf Therapeutics, Inc.
As of Oct 22, 2026, Werewolf Therapeutics is in Stage 2, the uptrend phase, now in week 5 (since Sep 23, 2026). It closed at $1.01, 42.9% below its 52-week high and above its 200-day average, which is rising.
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is HOWL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
HOWL among Biotechnology305th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …305 | HOWL | Stage 2 · wk 5 | 30 | +2.1% |
Werewolf Therapeutics: quick answers
What stage is Werewolf Therapeutics in?
As of Oct 22, 2026, Werewolf Therapeutics (HOWL) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 23, 2026 and is in week 5. What the four stages mean
Is Werewolf Therapeutics in an uptrend?
Yes. Werewolf Therapeutics is in a Stage 2 uptrend. It trades 50.9% above its 200-day average, which is rising.
How far is Werewolf Therapeutics from its 52-week high?
Werewolf Therapeutics closed at $1.01 on Oct 22, 2026, 42.9% below its 52-week high of $1.77. Its 52-week low is $0.31.
How has Werewolf Therapeutics performed over the past year?
As of Oct 22, 2026, Werewolf Therapeutics is down 37.3% over the past year and up 56.6% so far in 2026.
Which sector and industry is Werewolf Therapeutics in?
Werewolf Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.